Zepbound vs Ozempic 2026: Key Differences

See if you qualify with Nouri →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · cancel anytime

At a glance

	Zepbound®	Ozempic®
Active ingredient	Tirzepatide	Semaglutide
Drug class	Dual GIP + GLP-1 receptor agonist	GLP-1 receptor agonist
Manufacturer	Eli Lilly	Novo Nordisk
FDA-approved indication	Chronic weight management; obstructive sleep apnea in adults with obesity	Type 2 diabetes; cardiovascular risk reduction in T2D with established CVD
Dosing range	2.5 mg → 15 mg / week	0.25 mg → 2.0 mg / week
Administration	Once-weekly subcutaneous injection	Once-weekly subcutaneous injection
Weight-loss approval?	Yes (on-label)	No (off-label use)
Diabetes approval?	No	Yes (on-label)

Sources: FDA prescribing information for tirzepatide (updated 2025) and semaglutide (updated 2025). Efficacy figures are population averages from trials of the branded medications — not individual predictions.

Two different molecules

The pharmacological difference between Zepbound and Ozempic runs deeper than brand names. Tirzepatide (Zepbound) is a dual agonist, engineered to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. Semaglutide (Ozempic) activates only the GLP-1 receptor.

GLP-1 receptor agonists work by stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. The addition of GIP agonism in tirzepatide appears to enhance energy expenditure and fat breakdown beyond what GLP-1 activation alone produces — though the full mechanism behind tirzepatide's greater weight-loss effect is still being characterized in research.

This is a genuine pharmacological distinction, not merely a marketing difference. It helps explain why tirzepatide has shown larger average weight loss in clinical trials of the branded drugs, including in direct head-to-head comparison (see What the research shows, below).

Different FDA-approved uses

Zepbound® received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, or dyslipidemia). In 2024, the FDA also approved Zepbound specifically for obstructive sleep apnea (OSA) in adults with obesity — the first drug approved for that indication.

Ozempic® received FDA approval in 2017 for adults with type 2 diabetes to improve glycemic control, and in 2020 the label was expanded to include cardiovascular risk reduction in people with T2D and established cardiovascular disease.¹ Ozempic is not FDA-approved for weight management — that indication belongs to Wegovy® (semaglutide 2.4 mg), the higher-dose formulation from the same maker.

When people ask "Zepbound vs Ozempic for weight loss," the honest answer is: for pure weight loss, the on-label comparison is Zepbound vs Wegovy. Ozempic is a diabetes drug that is sometimes prescribed off-label for weight, but the FDA-cleared, higher-dose semaglutide weight-management product is Wegovy. See also: Ozempic vs Wegovy — what's the actual difference?

What the research shows

The key trials below studied the FDA-approved branded drugs. These results are for those specific products and do not represent expected outcomes for any compounded medication or for the Nouri program. Individual results vary.

STEP 1 — semaglutide 2.4 mg (Wegovy dose)

The STEP 1 trial (Wilding et al., NEJM 2021) studied once-weekly semaglutide 2.4 mg in adults with obesity without diabetes over 68 weeks. Participants receiving semaglutide 2.4 mg lost a mean of ~14.9% of body weight vs ~2.4% for placebo.² Note: this was the Wegovy dose, not the Ozempic diabetes dose.

SURMOUNT-1 — tirzepatide 5/10/15 mg (Zepbound)

The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) studied once-weekly tirzepatide in adults with obesity without diabetes over 72 weeks. The 15 mg dose produced a mean weight reduction of ~20.9%.³ These are results for the branded tirzepatide product studied in that trial.

SURMOUNT-5 — direct head-to-head

The SURMOUNT-5 trial (NEJM 2025) was the first head-to-head comparison of the branded tirzepatide (Zepbound) and branded semaglutide (Wegovy) products for weight management over 72 weeks in adults with obesity. Tirzepatide achieved a mean weight loss of ~20.2% versus ~13.7% for semaglutide — a statistically significant difference.⁴

Because SURMOUNT-5 compared Zepbound to Wegovy (not Ozempic), this reinforces that the appropriate weight-loss comparison is those two products — not Zepbound against Ozempic. These are branded-drug trial results; they do not describe outcomes for compounded tirzepatide or compounded semaglutide.

SELECT — semaglutide and cardiovascular outcomes

The SELECT trial (Lincoff et al., NEJM 2023) studied semaglutide 2.4 mg in adults with established cardiovascular disease and overweight/obesity but without diabetes. It showed approximately a 20% relative reduction in major adverse cardiovascular events (MACE) vs placebo.⁵ This was the semaglutide molecule at the weight-management dose; Ozempic's CV label approval covers people with type 2 diabetes and established CVD.

For a deeper look at how the underlying molecules compare across all indications, see: Tirzepatide vs Semaglutide: molecule-level comparison.

Side-effect profiles

Because both drugs activate the GLP-1 receptor, their side-effect profiles overlap significantly. The most common adverse effects for both include:

• Gastrointestinal: nausea, vomiting, diarrhea, constipation — most common early in treatment or after dose escalations, and typically transient.
• Reduced appetite: a desired therapeutic effect that can become a concern if caloric intake drops too low.
• Heart rate increase: both drugs are associated with a modest elevation in resting heart rate.

Both carry a boxed warning for thyroid C-cell tumors (based on rodent studies) and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Both are also contraindicated during pregnancy, and both carry risks of pancreatitis and gallbladder disease.^1,6

Head-to-head tolerability data comparing Zepbound and Ozempic specifically are limited; most comparisons in the literature pit Zepbound against Wegovy. Talk to your prescriber about your individual risk factors and history before starting either drug. For a full comparison of GLP-1 side-effect profiles, see: Which GLP-1 has the fewest side effects?

Cost and access in 2026

Both Zepbound and Ozempic are brand-name biologics with substantial list prices in the U.S. (as of June 2026, per manufacturer and public sources):

• Ozempic: list price roughly $900–$1,000 per month. With insurance covering a diabetes diagnosis, out-of-pocket cost may be lower; without insurance coverage it is often prohibitively expensive.
• Zepbound: self-pay through LillyDirect starting at approximately $299–$499/month depending on dose; standard list price can exceed $1,000/month. Novo Nordisk has a NovoCare savings program for eligible patients.

Insurance coverage varies widely. For weight management specifically, many plans still exclude coverage for Zepbound or Wegovy, making out-of-pocket cost a real barrier. For a current breakdown of brand and compounded pricing across GLP-1 therapies, see the GLP-1 cost guide (2026) and the live GLP-1 telehealth pricing dataset.⁷

For more on out-of-pocket brand pricing: Zepbound cost without insurance. For the broader brand vs compounded cost picture: Brand-name vs compounded GLP-1 cost comparison.

Who should consider each drug?

These drugs are not interchangeable. Their different approvals mean your health profile and goals drive which is appropriate — and that is a clinical determination, not a consumer preference:

Zepbound may be appropriate if:

• Your primary goal is weight management and you meet the BMI criteria (≥30 kg/m², or ≥27 with a weight-related condition).
• You want an on-label, FDA-approved weight-management therapy.
• You have obesity-related obstructive sleep apnea.
• You do not have type 2 diabetes as a primary indication (or your diabetes management is already addressed).

Ozempic may be appropriate if:

• You have type 2 diabetes and need glycemic control.
• You have type 2 diabetes with established cardiovascular disease and your provider wants to reduce CV risk.
• Your prescriber has determined semaglutide is the right molecule for your individual case (including off-label weight considerations, though Wegovy is the on-label weight product).

Neither drug is right for everyone. A licensed clinician evaluates your BMI, comorbidities, cardiovascular history, contraindications, and prior treatments before prescribing. The NIDDK overview of prescription medications for obesity provides a useful framework for understanding how prescribers approach this category.⁸

For the broadest look at which GLP-1 may produce the best outcomes by indication, see: Which GLP-1 is most effective for weight loss?

Can you switch from Ozempic to Zepbound?

Switching from a semaglutide product (Ozempic or Wegovy) to a tirzepatide product (Zepbound) is something some people do in consultation with a clinician. A few considerations:

• Restart at a low dose. Clinical guidance generally recommends starting tirzepatide at the lowest introductory dose (2.5 mg/week) regardless of the semaglutide dose you were on, to allow GI tolerance to the new molecule.
• The reason for switching matters. Poor tolerability, inadequate response, or a change in primary diagnosis (e.g., new T2D or new weight-management priority) are common reasons. Your provider should assess this.
• Timeline and washout. There is no required washout period between these drug classes, but transition timing is a clinical judgment.

The reverse switch — from tirzepatide to semaglutide — follows the same principles. Never change GLP-1 medications without a licensed provider managing the transition.

Related comparisons in this cluster

• Ozempic vs Wegovy — both semaglutide, different doses
• Tirzepatide vs Semaglutide — the molecules compared
• Brand-name vs compounded GLP-1 — cost, access, and key differences
• Compounded tirzepatide vs Zepbound
• Compounded semaglutide vs Wegovy

Where Nouri fits

If you and a licensed clinician decide a GLP-1 therapy is clinically appropriate for you, Nouri offers compounded semaglutide and compounded tirzepatide as part of one complete program — The Program includes clinician-guided GLP-1 treatment (when prescribed), a personalized nutrition plan, a movement plan, and ongoing support, all at one price, at any dose.

Important: Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not therapeutically equivalent to Ozempic®, Wegovy®, Zepbound®, or Mounjaro®. Nouri's compounded medications were not studied in the trials cited in this article. These are different products from different regulatory pathways. They are prescribed only when a licensed clinician determines it is clinically appropriate for the individual patient.

Medications are prepared by state-licensed 503A compounding pharmacies — Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX — and shipped discreetly to all 50 states. Pricing: compounded semaglutide from $120/mo on the 6-month plan ($720 billed semi-annually); compounded tirzepatide from $175/mo on the 6-month plan ($1,050 billed semi-annually). Same price at any dose. Nouri is LegitScript-certified.

Start your 5-minute assessment with Nouri →
Reviewed by a licensed clinician · The Nouri Promise: 30-day full refund on 3-month and 6-month plans · available in all 50 states

Frequently asked questions

Is Zepbound the same as Ozempic?

No. Zepbound® is tirzepatide (Eli Lilly), FDA-approved for weight management. Ozempic® is semaglutide (Novo Nordisk), FDA-approved for type 2 diabetes. They are different molecules, made by different companies, with different mechanisms and different approved indications. They are not interchangeable.

Which is better for weight loss, Zepbound or Ozempic?

For weight loss, Zepbound is the on-label, FDA-approved option; Ozempic is a diabetes drug. The on-label weight comparison is Zepbound vs Wegovy (the semaglutide weight-management product). In the SURMOUNT-5 head-to-head trial of those branded products, tirzepatide produced ~20.2% mean weight loss vs ~13.7% for semaglutide at 72 weeks — but those are population averages from trials of the branded drugs, not individual predictions. A clinician determines what is right for you.

Can I use Ozempic for weight loss?

Ozempic is not FDA-approved for weight management. It is sometimes prescribed off-label for weight, but the on-label, FDA-cleared weight-management product from the same drug class is Wegovy (semaglutide 2.4 mg). Whether Ozempic, Wegovy, Zepbound, or another approach is right for you is a clinical decision.

Is Zepbound stronger than Ozempic for weight loss?

In the SURMOUNT-5 head-to-head trial, the branded tirzepatide product showed greater average weight reduction than the branded semaglutide product (~20.2% vs ~13.7% at 72 weeks). That trial compared Zepbound and Wegovy, however — not Ozempic. These are population averages from trials of the branded medications; individual response varies substantially.

Can I switch from Ozempic to Zepbound?

Some patients transition from a semaglutide to a tirzepatide product under clinical supervision. Clinical guidance generally recommends restarting at tirzepatide's lowest introductory dose (2.5 mg/week) regardless of your prior semaglutide dose. A licensed provider should manage the timing, dosing, and clinical rationale for any switch.

Do Zepbound and Ozempic have the same side effects?

Both drugs activate the GLP-1 receptor, so they share a broadly similar GI side-effect profile: nausea, vomiting, diarrhea, constipation — especially early in treatment. Both also carry the same boxed warning for thyroid C-cell tumors and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2. Both are contraindicated in pregnancy. Side-effect intensity varies by individual; discuss your complete history with your prescriber.

Sources & references

1. Ozempic (semaglutide) FDA prescribing information, 2025
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM. 2022.
4. SURMOUNT-5 — tirzepatide vs semaglutide head-to-head. NEJM. 2025.
5. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM. 2023.
6. Zepbound (tirzepatide) FDA prescribing information, 2025
7. Nouri GLP-1 telehealth pricing dataset, 2026 (HuggingFace)
8. NIDDK — Prescription medications to treat overweight and obesity
9. FDA — Human drug compounding

Medically reviewed by Amber Patel, MD. Authored by the Nouri Editorial Team. Nouri content is reviewed by licensed clinicians and updated as guidance changes. Last reviewed June 29, 2026.

This article is general health education, not medical advice. Talk to a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. Clinical trial results described in this article are from studies of the FDA-approved branded medications; compounded semaglutide and compounded tirzepatide were not studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name drugs. GLP-1 medications carry a boxed warning for thyroid C-cell tumors (seen in animal studies; human relevance unknown) and are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN 2). Other risks include pancreatitis and gallbladder disease. GLP-1 medications are not approved for use in pregnancy. Prices cited are as of June 2026 and are subject to change; verify current pricing with your pharmacy or provider. Brand prices are from publicly available manufacturer sources and insurance pricing varies.